Amundi
FATE icon

Amundi’s Fate Therapeutics FATE Stock Holding History

Amundi’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,990
Closed -$15.3K – 2165
2024
Q3 		$15.3K Hold
4,990
– – ﹤0.01% 1917
2024
Q2 		$15.8K Buy
+4,990
New +$21.8K ﹤0.01% 1860
2023
Q4 		– Sell
-7,154
Closed -$12.2K – 2024
2023
Q3 		$12.2K Hold
7,154
– – ﹤0.01% 1965
2023
Q2 		$34.5K Hold
7,154
– – ﹤0.01% 1927
2023
Q1 		$39.3K Sell
7,154
-4,664
-39% -$28.1K ﹤0.01% 1909
2022
Q4 		$67.6K Sell
11,818
-70,030
-86% -$1.32M ﹤0.01% 1657
2022
Q3 		$1.93M Sell
81,848
-153,845
-65% -$4.45M ﹤0.01% 1157
2022
Q2 		$7.43M Sell
235,693
-121,846
-34% -$3.36M 0.01% 839
2022
Q1 		$14.1M Sell
357,539
-23,595
-6% -$914K 0.01% 738
2021
Q4 		$16.1M Sell
381,134
-18,520
-5% -$1.05M 0.01% 732
2021
Q3 		$23.7M Sell
399,654
-8,833
-2% -$693K 0.02% 648
2021
Q2 		$35.5M Buy
+408,487
New +$32.9M 0.02% 525

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Amundi's FATE Position: Q4 2024 in Review

Amundi sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 4,990 shares — an estimated $15.3K sold.

Amundi first reported a position in FATE in Q2 2021 and held it in 12 quarters. The position peaked at $35.5M in Q2 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Amundi reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Amundi sold 4,990 Fate Therapeutics shares in Q4 2024, an estimated $15.3K.
  • Amundi first reported a position in Fate Therapeutics in Q2 2021 and held it in 12 quarters.
  • Amundi's Fate Therapeutics position peaked at $35.5M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Amundi's 13F filing for Q4 2024, filed 7 Feb 2025.